Category: News

DRI Healthcare Trust Reports First Quarter 2023 Results

– Robust royalty transaction activity showcases ability to execute on attractive deals – – Continued strong performance of existing assets and financial results – TORONTO, May 11, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced its financial results for the quarter ended March 31, 2023. The Trust’s first […]

DRI Healthcare Trust Announces Participation in Upcoming Investor Conferences

TORONTO, May 10, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced that the Trust intends to participate in the following investor conferences in spring 2023: RBC Global Healthcare Conference Date: May 17, 2023 Presentation time: 2:30 pm ET City: New York, New York UBS Spring Biotech Conference Date: May […]

DRI Healthcare Trust to Host First Quarter Earnings Call and Webcast on May 12, 2023

TORONTO, April 27, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today that it will hold a conference call to discuss its first quarter financial results on Friday, May 12, 2023, at 8:00 a.m. ET. The Trust will report its financial results on Thursday, May 11, 2023, after […]

DRI Healthcare Trust Announces Sale of its TZIELD™ Royalty Interest to Sanofi for US$210 Million and Announces a US$20 Million Special Cash Distribution to Unitholders

– Transaction will allow DHT to redeploy capital into new deals generating compounding returns for unitholders – TORONTO, April 27, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“the Trust”) announces that its wholly-owned subsidiary has sold its royalty interest and milestone payment obligations in the worldwide sales of TZIELD™ to a subsidiary […]

DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of TZIELD™ (teplizumab-mzwv) and Updates Long-Term Cash Receipts Outlook

– Transaction adds a ground-breaking type 1 diabetes therapy to DRI’s expanding portfolio – – Excluding any new transactions, DRI now expects 2030 cash receipts to be at least as high as 2022 cash receipts – – Extends DRI’s overall portfolio duration to over 10 years – TORONTO, March 8, 2023 /CNW/ – DRI Healthcare […]

DRI Healthcare Trust Reports Fourth Quarter and Fiscal 2022 Results

– 2022 deployment of US$281 million continues to validate growth strategy – – Continued strong performance of existing assets and financial results – TORONTO, March 1, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022. […]

DRI Healthcare Trust Announces US$95 million Private Placement of Preferred Securities and Increased Deployment Target

– Provides additional capital to fund biopharmaceutical research, driving value for DRI’s unitholders and partners –  TORONTO, Feb. 8, 2023 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (“DRI” or “the Trust”) announced today that it has completed a private placement of US$95 million of preferred securities (the “Private Placement”) to an investor group that […]